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Background:  Increased cardiovascular events in patients on clopidogrel have been associated with polymorphism of the CYP2C19 gene (which is 
associated with abnormal clopidogrel metabolism), and high on-treatment platelet reactivity (HPR) as determined using the VerifyNow P2Y12 assay. 
Despite evidence that both HPR and polymorphism of the CYP2C19 gene identifies patients at risk for subsequent events, there are limited data 
regarding the correlation between these two tests.
Methods:  We prospectively identified 171 outpatients taking 75 mg of clopidogrel with a history of percutaneous coronary intervention (PCI) and 
tested for HPR (defined as more than 234 platelet reactivity units) using the VerifyNow P2Y12 assay, and for loss-of-function alleles of the CYP2C19 
locus-using a TaqMan allelic discrimination assay. 
Results:  We identified 56 patients with HPR by VerifyNow and 57 patients with at least one loss-of-function (2C19*2) allele (abnormal 
metabolizers). Using VerifyNow as a screening test, the sensitivity and specificity for identifying abnormal metabolizer status was 52.6% and 77.2% 
and the positive predictive value (PPV) and negative predictive value (NPV) were 53.6% and 76.5%. Using CYP2C19 genotyping as a screening test, 
the sensitivity and specificity for identifying HPR was 53.6%and 76.5% and PPV and NPV were 52.6% and 77.2%. Using a combination of the two 
tests, 83 patients (48.5%) were identified as being at risk for clopidogrel resistance. 
Conclusions:  Clopidogrel resistance as identified by VerifyNow performs poorly as a screening test to identify abnormal metabolizer status. 
Likewise, using 2C19 genotyping as a screening exam performs poorly when the goal is to identify HPR. Almost half of all outpatients with previous 
PCI were found to be at risk for clopidogrel resistance, which suggests that combined outpatient screening may be needed to optimize dual 
antiplatelet therapy. 
